Pacira BioSciences
PCRX
284 hedge funds and large institutions have $2.82B invested in Pacira BioSciences in 2022 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 106 increasing their positions, 105 reducing their positions, and 48 closing their positions.
1% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 105
2.99% less ownership
Funds ownership: 110.73% → 107.74% (-3%)
6% less funds holding
Funds holding: 301 → 284 (-17)
19% less capital invested
Capital invested by funds: $3.48B → $2.82B (-$657M)
21% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 48
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
84% less call options, than puts
Call options by funds: $2.43M | Put options by funds: $15.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$46.9M |
| 2 |
Jennison Associates
New York
|
+$27.1M |
| 3 |
DM
Deerfield Management
New York
|
+$19.1M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$10.7M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$32.6M |
| 2 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$26.9M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$15.4M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$12.1M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
-$11.2M |
PCRX Hedge Fund Activity: Q2 2022 in Review
284 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2022, worth a combined $2.82B — down 19% from $3.48B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of PCRX and 38 opened new positions — a net loss of 10 holders — while 105 trimmed existing stakes and 106 added.
The largest buyer was Invesco, adding an estimated $46.9M. The largest seller was Macquarie Group, cutting an estimated $32.6M.
- 284 institutional investors held Pacira BioSciences (PCRX) as of Q2 2022, down from 301 in Q1 2022.
- Funds reported $2.82B of Pacira BioSciences stock for Q2 2022, down 19% quarter-over-quarter.
- 38 funds opened new Pacira BioSciences positions in Q2 2022 and 48 closed out, a net change of -10 holders.
- The largest Pacira BioSciences buyer in Q2 2022 was Invesco, an estimated $46.9M added.
- The largest Pacira BioSciences seller in Q2 2022 was Macquarie Group, an estimated $32.6M sold.
Based on aggregated 13F filings for Q2 2022.